Sofosbuvir and Ribavirin to Treat Hepatitis C Virus Genotype 4 Infection in a 65-Year-Old Patient With Diabetes and Low Platelet: A Case Report

Hepatitis C virus (HCV) is a major public health problem especially in the elderly. The classical interferon/ribavirin regimen was unfavorable for elderly patents due to intolerability and adverse effects. More studies are needed about the safety profile of new direct-acting antiviral (DAA) in the elderly. Here, a case of chronic HCV was described in a 65-year-old female with diabetes and low platelet count. The patient was treated successfully by a combination of sofosbuvir+ ribavirin without major side effects. This report highlighted the importance and the safety of this regimen to treat HCV in the elderly.